Low-risk PCa: Higher radiation dose shows no benefit

Higher radiation doses don’t confer a survival benefit in men with low-risk prostate cancer, although they do increase survival rates for men with medium- and high-risk cancers, the authors of a new study report.

The retrospective, nonrandomized study, which was published online in JAMA Oncology (July 15, 2015), used information from the National Cancer Database to evaluate 42,481 men diagnosed with non-metastatic prostate cancer between 2004 and 2006. Researchers followed the men through 2012. They divided patients into three cohorts: low-risk (12,229 men), intermediate-risk (16,714 men), and high-risk (13,538 men), and categorized the members of each cohort according to whether they were treated with standard-dose or escalated-dose external beam radiation therapy (EBRT). The standard dose was 68.4 Gy to <75.6 Gy (1 Gy=100 rad); the escalated dose was 75.6 Gy to 90 Gy.

The authors then compared overall survival rates between treatment groups in each cohort and performed a secondary analysis of dose response for survival. Men in the low-risk cancer group showed no difference in survival regardless of radiation dose. The intermediate-risk group showed a 7.8% decrease in the risk of death for every incremental increase of about 2 Gy in radiation dose, and the high-risk group showed a 6.8% reduction for each incremental dosage increase.

The 7-year adjusted survival rate for low-risk men was 86% in both the standard- and escalated-dose groups. Intermediate-risk men in the escalated-dose group had an 82% survival rate compared with 78% for men in the standard-dose group. Survival rates for high-risk men were 74% in the escalated-dose group and 69% in the standard-dose group.

0 Comments

You must be signed in to leave a comment. Registering is fast and free!

All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.